Results 181 to 190 of about 1,615,709 (243)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers: Multidatabase Target Trial Emulation Studies. [PDF]

Hypertension
Xie C, Chen R, Zhou S, Lin Y, Liu J, Su L, Pang M, Guo Z, Luo F, Chen L, Kong Y, Nie S.   +11 more
europepmc   +1 more source

Incidence of Childhood Dilated Cardiomyopathy in Sweden From 1991 to 2019: A National Population‐Based Study

Acta Paediatrica, EarlyView.
ABSTRACT Aim To study the incidence, survival, and mortality of dilated cardiomyopathy (DCM) in children in Sweden, 1991–2019. Methods Hospital records of 0–18‐year‐olds diagnosed with DCM over a 29‐year period were reviewed. The annual sex‐specific incidence rates of DCM were calculated as new disease cases, divided by the average Swedish same‐sex ...
Shalan Fadl, Stefan Särnblad, Tahir Taj, Håkan Wåhlander, Eva Fernlund, Jan Sunnegårdh   +5 more
wiley   +1 more source

Angiotensin-Converting Enzyme Inhibitors to Prevent Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Scientific Speculation or an Opportunity to Improve Real Clinical Practice? [PDF]

Int J Mol Sci
Seidita A, Buscemi C, Di Liberto D, Pistone M, Maestri S, Cavallo G, Cosenza S, Spagnuolo G, Giuliano A, Carlisi D, Pratelli G, Mandreucci F, Carroccio A.   +12 more
europepmc   +1 more source

Medication Use and Risk of Microscopic Colitis: A Propensity‐Matched Analysis of US Adults ≥ 50 Years (2014–2024)

Alimentary Pharmacology &Therapeutics, EarlyView.
Commonly prescribed NSAIDs, PPIs and SSRIs were associated with a higher risk of microscopic colitis after propensity score matching, whereas ACE inhibitors, ARBs and statins showed no significant association. ABSTRACT Background The association between medications—including non‐steroidal anti‐inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs ...
Yassine Kilani, Farah Heis, Andrew Dugaesescu, Youssef Hafez, Shadi Hamdeh, Wissam Kiwan, Mahmoud Y. Madi   +6 more
wiley   +1 more source

Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors in Heart Failure Patients With Reduced Ejection Fraction: A Cross Sectional Study on Implications for Guideline-Targeted Therapy. [PDF]

Health Sci Rep
Kampamba M, Mbanvu R, Hangoma J, Mwalungali G, Mutenda M, Hamachila A.   +5 more
europepmc   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Angiotensin-Converting Enzyme Inhibitors Mitigate Development of Chronic Persistent Cardiac Dysfunction Following Fulminant Myocarditis: A Multicenter Retrospective Study in China. [PDF]

Int J Gen Med
Yang H, Qidamugai W, Wang L, Liu F, He Y, Xu Z, Zhang L, Li F, Wang H, Jiang J.   +9 more
europepmc   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period: withdraw or continue? A multicentre randomised controlled trial. [PDF]

Br J Anaesth
Miggelbrink LA, van Klei WA, Verhaar MC, Asselbergs FW, Spiering W, Buhre WFFA, Hollmann MW, van Lier F, van Dongen EHPA, Schober P, Rettig TCD, Reitsma HJB, van Schaik EPC, Vernooij LM, van Waes JAR.   +14 more
europepmc   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source